Life Sciences

Pfizer accused of suppressing Neurontin study

Pharma Compliance Alert, October 15, 2008

Pfizer marketing executives allegedly knew Neurontin, an epilepsy drug, did not effectively treat other conditions and delayed the publication or altered the conclusions of studies to boost off-label sales through at least 2003, according to a Boston Globe article.

Post a Comment

Name:

 

E-mail:

 

Please enter your comment below:

   

Please enter the text below:

   
   

Most Popular